Clinical Trial

An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

Study acronym: RaPTR-101
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-17.
Status change: Not Yet Recruiting → Recruiting 2026-02-12
Trial Details
NCT Number NCT07293754
Lead Sponsor Repertoire Immune Medicines
Conditions Advanced Malignant Solid Tumor
Enrollment 150 participants
Start Date 2025-12-12
Primary Completion 2028-12-15 (estimated)
Study Completion 2029-04-15 (estimated)
Updated on ClinicalTrials.gov 2026-02-17